drugset / Trial / NCT06400472
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Timeline
- Start
- 2024-05-20
- Primary completion
- 2027-02
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Itraconazole | Small molecule | — | Oral |
| Subject | LY4170156 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |